Bristol Myers Squibb teams up with GentiBio to create cell therapies for Crohn’s other conditions
New England Council member, Bristol Myers Squibb has partnered with GentiBio to research new cell therapies for autoimmune and inflammatory conditions. Together these two companies will develop treatments that stop immune responses to aid people with inflammatory bowel disease including Crohn’s and ulcerative colitis. As other biotech firms have focused on cancer, this partnership will be a unique focus on how autoimmune diseases will affect up to 3.5 million people by the year 2030.
The cell therapy put forth by Bristol Myers Squibb and GentiBio will use regulatory T cells which will be aimed at controlling inflammation. Using these specific cells biomedical engineers to target the inflammation in the intestines, stop any out unruly response by the immune system and start the healing process. Along with cell therapy, bioengineers will work on a complimentary pill to work as a kind of ‘remote control’ which can allow doctors to adjust the response of the T-cells depending on the patient.
Cofounder and chief executive of GentiBio said “[w]e’re excited to work with a well-established partner such as BMS, given the size of the indication and given the potential impact.”
The New England Council would like to commend Bristol Myers Squibb and its new partner GentiBio for its dedicated work developing new therapies.
Read more from the Boston Globe.